DALLAS, April 22, 2015 /PRNewswire/ --
RnRMarketResearch.com adds Herpes Zoster (Shingles) - Pipeline Review, H1 2015 market research report of 61 pages published in March 2015 to its life sciences industry intelligence collection for 2015 and beyond.
The ‘Herpes Zoster (Shingles) - Pipeline Review, H1 2015 research report provides comprehensive information on the therapeutic development for Herpes Zoster (Shingles), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Zoster (Shingles) and special features on late-stage and discontinued projects. Complete report is available at http://www.rnrmarketresearch.com/herpes-zoster-shingles-pipeline-review-h1-2015-market-report.html .
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The research provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles). It reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. The report reviews key players involved in the therapeutics development for Herpes Zoster (Shingles) and enlists all their major and minor projects and also summarizes all the dormant and discontinued pipeline projects. A review of the Herpes Zoster (Shingles) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources is covered along with pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. A detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Herpes Zoster (Shingles) pipeline on the basis of target, MoA, route of administration and molecule type as well as latest news and deals relating related to pipeline products are provided in this report.
Companies Involved in Herpes Zoster Therapeutics Development and mentioned in this research include Astellas Pharma Inc., Epiphany Biosciences, Inc., Foamix Pharmaceuticals Ltd., GlaxoSmithKline plc, Merck & Co., Inc., NAL Pharmaceuticals Ltd. and Spider Biotech. Drug profiles for acyclovir, amenamevir, FV-100, GSK-1437173A, NAL-3221, NAL-3223, SB105-A10, V-212 and valomaciclovir stearate are covered in this research on Herpes Zoster therapeutics pipeline review. Order a copy of this research at http://www.rnrmarketresearch.com/contacts/purchase?rname=365323 .
Data Tables provided in this research include:
Number of Products under Development for Herpes Zoster (Shingles), H1 2015 Number of Products under Development for Herpes Zoster (Shingles) - Comparative Analysis, H1 2015 Number of Products under Development by Companies, H1 2015 Comparative Analysis by Late Stage Development, H1 2015 Comparative Analysis by Clinical Stage Development, H1 2015 Comparative Analysis by Early Stage Development, H1 2015 Comparative Analysis by Unknown Stage Development, H1 2015 Products under Development by Companies, H1 2015 Herpes Zoster (Shingles) - Pipeline by Astellas Pharma Inc., H1 2015 Herpes Zoster (Shingles) - Pipeline by Epiphany Biosciences, Inc., H1 2015 Herpes Zoster (Shingles) - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline plc, H1 2015 Herpes Zoster (Shingles) - Pipeline by Merck & Co., Inc., H1 2015 Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd., H1 2015 Herpes Zoster (Shingles) - Pipeline by Spider Biotech, H1 2015 Assessment by Monotherapy Products, H1 2015 Number of Products by Stage and Target, H1 2015 Number of Products by Stage and Mechanism of Action, H1 2015 Number of Products by Stage and Route of Administration, H1 2015 Number of Products by Stage and Molecule Type, H1 2015 Herpes Zoster (Shingles) Therapeutics - Recent Pipeline Updates, H1 2015 Herpes Zoster (Shingles) - Dormant Projects, H1 2015 Herpes Zoster (Shingles) - Discontinued Products, H1 2015
Another research on Valaciclovir - Comprehensive patent search covers information and data on:
International Nonproprietary Name: Valaciclovir
Indications: Herpes zoster; Herpes simplex; Genital herpes
Innovator: GlaxoSmithKline (Valtrex)
The In-depth search contains patents from territories that are individually verified and monitored for changes, including British, German, Spanish, French, US, Canadian, Australian, European, and PCT patents.
Explore more reports on the therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .
RnRMarketResearch.com adds Herpes Zoster (Shingles) - Pipeline Review, H1 2015 market research report of 61 pages published in March 2015 to its life sciences industry intelligence collection for 2015 and beyond.
Advertisement
The ‘Herpes Zoster (Shingles) - Pipeline Review, H1 2015 research report provides comprehensive information on the therapeutic development for Herpes Zoster (Shingles), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Zoster (Shingles) and special features on late-stage and discontinued projects. Complete report is available at http://www.rnrmarketresearch.com/herpes-zoster-shingles-pipeline-review-h1-2015-market-report.html .
Advertisement
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The research provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles). It reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. The report reviews key players involved in the therapeutics development for Herpes Zoster (Shingles) and enlists all their major and minor projects and also summarizes all the dormant and discontinued pipeline projects. A review of the Herpes Zoster (Shingles) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources is covered along with pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. A detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Herpes Zoster (Shingles) pipeline on the basis of target, MoA, route of administration and molecule type as well as latest news and deals relating related to pipeline products are provided in this report.
Companies Involved in Herpes Zoster Therapeutics Development and mentioned in this research include Astellas Pharma Inc., Epiphany Biosciences, Inc., Foamix Pharmaceuticals Ltd., GlaxoSmithKline plc, Merck & Co., Inc., NAL Pharmaceuticals Ltd. and Spider Biotech. Drug profiles for acyclovir, amenamevir, FV-100, GSK-1437173A, NAL-3221, NAL-3223, SB105-A10, V-212 and valomaciclovir stearate are covered in this research on Herpes Zoster therapeutics pipeline review. Order a copy of this research at http://www.rnrmarketresearch.com/contacts/purchase?rname=365323 .
Data Tables provided in this research include:
Number of Products under Development for Herpes Zoster (Shingles), H1 2015 Number of Products under Development for Herpes Zoster (Shingles) - Comparative Analysis, H1 2015 Number of Products under Development by Companies, H1 2015 Comparative Analysis by Late Stage Development, H1 2015 Comparative Analysis by Clinical Stage Development, H1 2015 Comparative Analysis by Early Stage Development, H1 2015 Comparative Analysis by Unknown Stage Development, H1 2015 Products under Development by Companies, H1 2015 Herpes Zoster (Shingles) - Pipeline by Astellas Pharma Inc., H1 2015 Herpes Zoster (Shingles) - Pipeline by Epiphany Biosciences, Inc., H1 2015 Herpes Zoster (Shingles) - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline plc, H1 2015 Herpes Zoster (Shingles) - Pipeline by Merck & Co., Inc., H1 2015 Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd., H1 2015 Herpes Zoster (Shingles) - Pipeline by Spider Biotech, H1 2015 Assessment by Monotherapy Products, H1 2015 Number of Products by Stage and Target, H1 2015 Number of Products by Stage and Mechanism of Action, H1 2015 Number of Products by Stage and Route of Administration, H1 2015 Number of Products by Stage and Molecule Type, H1 2015 Herpes Zoster (Shingles) Therapeutics - Recent Pipeline Updates, H1 2015 Herpes Zoster (Shingles) - Dormant Projects, H1 2015 Herpes Zoster (Shingles) - Discontinued Products, H1 2015
Another research on Valaciclovir - Comprehensive patent search covers information and data on:
International Nonproprietary Name: Valaciclovir
Indications: Herpes zoster; Herpes simplex; Genital herpes
Innovator: GlaxoSmithKline (Valtrex)
The In-depth search contains patents from territories that are individually verified and monitored for changes, including British, German, Spanish, French, US, Canadian, Australian, European, and PCT patents.
Explore more reports on the therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .
About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets (http://www.rnrmarketresearch.com/report-index ). With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
Twitter: https://twitter.com/RnRMR
Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345
RSS / Feeds: http://www.rnrmarketresearch.com/feed
Market Research Blog: http://www.rnrmarketresearch.com/blog/
Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
[email protected]
SOURCE RnR Market Research
